Tech Company Financing Transactions

Araris Biotech Funding Round

Araris Biotech secured a $24 million funding round on 10/5/2022. Investors included 4BIO Capital, Pureos Bioventures and btov Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Riedhofstrasse 11
Zurich, 8804
CH

Phone

Undisclosed

Website

www.ararisbiotech.com

Email Address

Undisclosed

Overview

Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology. Our linker platform enables payload attachment to 'off-the-shelf' antibodies in one step without needing to re-engineer or reduce antibodies, resulting in highly homogenous, stable and potent ADC therapies.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Philipp Spycher

        

Co-Founder

Isabella Toller

        

Browse more venture capital transactions:

Prev: 10/5/2022: Xembly venture capital transaction
Next: 10/5/2022: Aptoide venture capital transaction

Share this article

Where The Data Comes From

We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary